Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme

International Journal of Radiation Oncology, Biology, Physics

Volumn 33, Issue 2, 1995, Pages 357-364

  Levin, V A ^a   Maor, M H ^a   Thall, P F ^a   Yung, W K A ^a   Bruner, J ^a   Sawaya, R ^a   Kyritsis, A P ^a   Leeds, N ^a   Woo, S ^b   Rodriguez, L ^c   Gleason, M J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c Memorial Hospital   (United States)

Author keywords

Accelerated fractionated radiotherapy; Carboplatin; Glioblastoma; PCV

Indexed keywords

CARBOPLATIN; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RADIATION NECROSIS; REOPERATION; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMAN; LOMUSTINE; MIDDLE AGE; PROCARBAZINE; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0029161882     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)00160-Z     Document Type: Article

References (42)

1. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines
2. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytomas
3. Clinical status of carboplatin
4. Robust locally weighted regression and smoothing scatterplots
5. Regression models and life tables
6. Sample size considerations for studies comparing survival curves using histroical controls
7. Carboplatin as a potentiator of radiation therapy
8. A pilot study of cis-diamminedichloroplatinum and radiation therapy in high grade astrocytomas
9. The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma
10. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion
11. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I–II dose response study
12. Planning the size and duration of a clinical trial studying the time to some critical event
13. Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation
14. Proportional hazards tests and diagnostics based on weighted residuals
15. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2
16. European organization for research on treatment of cancer trials using radiotherapy with multiple fractions per day
17. Nonparametric estimates from incomplete observations
18. Survival and quality of life after continuous accelerated radiotherapy of glioblastoma
19. Radiation therapy for neoplasms of the brain
20. Neoplasms of the central nervous system
21. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
22. NCOG protocol 6G91: Seven drug chemotherapy and irradiation for patients with glioblastoma multiforme
23. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas
24. Criteria for evaluating malignant brain tumor patients undergong chemotherapy
25. A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and hydroxyurea for primary malignant gliomas
26. Radiosurgery as part of the initial management of patients with malignant gliomas
27. Combination of radiotherapy and drugs for the treatment of malignant gliomas
28. Cerebral radio-necrosis: Incidence and risk in relation to dose, time, fractionation and volume
29. The exact analysis of contingency tables in medical research
30. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study
31. Radiation and platinum drug interaction
32. Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California cancer center phase II study
33. Phase I study of carboplatin given on a five-day intravenous schedule
34. Martingale-based residuals for Survival Models
35. A package for survival analysis in S. Mayo foundation
36. Radiation and nitroimidazoles in supratentorial high grade gliomas: A second clinical trial
37. Cisplatin in the treatment of rcurrent childhood primary brain tumors
38. Intravenous carboplatin for recurrent malignant gliomas: A phase II study
39. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum (II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity